https://healix.net/news/meet-the-healix-team-at-idweek-2026/2026-05-26T15:54:43-04:00https://healix.net/news/join-our-team-at-norm-2026/2026-05-26T16:07:52-04:00https://healix.net/news/singlepoint-healthcare-acquires-healix-expanding-national-infusion-capabilities/2026-07-05T20:51:34-04:00https://healix.net/events/lets-connect-at-the-2026-cmsc-annual-meeting/2026-04-17T17:14:11-04:00https://healix.net/events/lets-connect-at-the-2026-aan-annual-meeting/2026-03-19T17:56:42-04:00https://healix.net/events/immunology2026-annual-meeting/2026-03-19T10:39:34-04:00https://healix.net/events/state-of-texas-association-of-rheumatologists-star-2026-annual-meeting/2026-03-11T16:27:02-04:00https://healix.net/news/real-world-retrospective-cohort-study-evaluating-the-tolerability-of-immune-globulin-intravenous-10-bivigam/2026-03-03T12:39:21-05:00https://healix.net/news/real-world-adherence-and-effectiveness-of-inclisiran-in-lowering-ldl-c/2026-03-03T12:21:45-05:00https://healix.net/news/rezzayo-proves-effective-in-candidemia-candidiasis/2026-08-11T06:09:38-04:00https://healix.net/clinical-outcomes/evaluation-of-fecal-microbiota-live-jslm-by-standard-of-care-antibiotic-washout-period-for-the-prevention-of-recurrent-clostridioides-difficile-infection/2025-12-03T13:07:27-05:00https://healix.net/clinical-outcomes/efficacy-and-safety-of-rezafungin-a-long-acting-echinocandin/2025-11-03T15:42:18-05:00https://healix.net/clinical-outcomes/real-world-effectiveness-and-health-related-quality-of-life-improvements-using-fecal-microbiota-live-jslm-for-the-prevention-of-recurrent-clostridioides-difficile-infection/2025-11-03T15:38:11-05:00https://healix.net/clinical-outcomes/long-term-effectiveness-of-long-acting-cabotegravir-and-rilpivirine-in-an-infectious-disease-office-based-hiv-program/2025-11-03T15:31:51-05:00https://healix.net/news/meet-the-healix-team-at-idweek-2025/2025-10-08T16:30:55-04:00https://healix.net/news/chest-annual-meeting-2025/2025-10-08T16:29:44-04:00https://healix.net/clinical-outcomes/real-world-experience-with-rezafungin-a-novel-long-acting-echinocandin/2025-04-23T16:09:07-04:00https://healix.net/clinical-outcomes/immune-globulin-subcutaneous-16-5-in-immunoglobulin-naive-patients-with-primary-immunodeficiency/2025-04-17T16:41:27-04:00https://healix.net/clinical-outcomes/real-world-effectiveness-and-onset-of-action-of-vedolizumab-as-a-first-line-biologic-in-biologic-naive-patients-with-ulcerative-colitis/2024-11-14T13:33:28-05:00https://healix.net/clinical-outcomes/effectiveness-of-a-community-based-inflammatory-bowel-disease-medical-home-compared-to-patients-not-in-a-medical-home/2025-11-12T20:49:32-05:00https://healix.net/clinical-outcomes/immune-globulin-subcutaneous-16-5-in-treatment-of-primary-immunodeficiency-a-two-year-multi-center-analysis/2024-11-14T13:33:00-05:00https://healix.net/clinical-outcomes/telavancin-outcomes-in-infections-treated-with-outpatient-parenteral-antibiotic-therapy-opat/2024-11-14T13:32:17-05:00https://healix.net/clinical-outcomes/optimal-vancomycin-model-selection-for-obese-patients-receiving-outpatient-parenteral-antimicrobial-therapy-opat/2024-11-14T13:31:45-05:00https://healix.net/new-therapies-programs/real-world-effectiveness-of-fecal-microbiota-live-jslm-for-the-prevention-of-recurrent-clostridioides-difficile-infection/2024-11-14T13:31:16-05:00https://healix.net/new-therapies-programs/infectious-disease-physician-office-based-hiv-program-results-in-successful-adherence-of-therapy-in-patients-receiving-long-acting-cabotegravir-and-rilpivirine/2024-11-14T13:30:51-05:00https://healix.net/new-therapies-programs/biologic-therapy-sequencing-in-ulcerative-colitis-a-real-world-observational-study-of-second-line-therapy-after-vedolizumab/2024-11-14T13:30:05-05:00https://healix.net/new-therapies-programs/real-world-outcomes-of-a-novel-fecal-microbiome-replacement-treatment-for-the-prevention-of-recurrent-clostridioides-difficile-infection-a-multicenter-study/2024-11-14T13:29:28-05:00https://healix.net/new-therapies-programs/real-world-experience-of-a-simple-administration-of-a-novel-fecal-microbiome-replacement-for-prevention-of-recurrent-clostridioides-difficile-2/2024-11-14T13:28:52-05:00https://healix.net/new-therapies-programs/real-world-experience-of-a-simple-administration-of-a-novel-fecal-microbiome-replacement-for-prevention-of-recurrent-clostridioides-difficile/2024-11-14T13:28:19-05:00https://healix.net/clinical-outcomes/reductions-in-ldl-c-within-the-first-year-of-treatment-with-inclisiran-results-from-a-multicenter-real-world-cohort/2024-11-14T13:27:27-05:00https://healix.net/clinical-outcomes/immune-globulin-subcutaneous-16-5-in-the-treatment-of-primary-immunodeficiency-a-two-year-multicenter-analysis/2024-11-14T13:26:50-05:00https://healix.net/new-therapies-programs/early-experience-with-a-simple-administration-of-a-novel-fecal-microbiome-replacement-for-prevention-of-recurrent-clostridioides-difficile/2024-11-14T13:26:19-05:00https://healix.net/clinical-outcomes/real-world-outcomes-with-subcutaneous-immunoglobulin-16-5-in-the-treatment-of-primary-immunodeficiency/2024-11-14T13:25:27-05:00https://healix.net/clinical-outcomes/real-world-outcomes-after-switching-to-immune-globulin-subcutaneous-16-5-in-patients-with-primary-humoral-immunodeficiency-a-3-year-study/2024-11-14T13:24:39-05:00https://healix.net/clinical-outcomes/treatment-with-intravenous-immune-globulin-10-in-a-real-world-outpatient-setting/2024-11-14T13:24:07-05:00https://healix.net/new-therapies-programs/characteristics-associated-with-inclisiran-initiation-in-outpatient-physician-clinics/2024-11-14T13:23:32-05:00https://healix.net/clinical-outcomes/long-term-outcomes-with-immune-globulin-subcutaneous-16-5-in-treatment-of-primary-immunodeficiency/2024-11-14T13:22:44-05:00https://healix.net/new-therapies-programs/real-world-use-of-inclisiran-in-outpatient-physician-clinics/2024-11-14T13:22:00-05:00https://healix.net/clinical-outcomes/epstein-barr-virus-associated-ulcers-in-a-patient-with-ulcerative-colitis-taking-vedolizumab-a-case-report/2024-11-14T13:21:20-05:00https://healix.net/clinical-outcomes/ileocecal-stricture-as-a-manifestation-of-disseminated-histoplasmosis-in-an-immunosuppressed-patient-a-case-report/2024-11-14T13:20:21-05:00https://healix.net/clinical-outcomes/real-world-immune-globulin-subcutaneous-16-5-use-in-treatment-naive-patients-with-primary-immunodeficiency/2024-11-14T13:19:38-05:00https://healix.net/clinical-outcomes/real-world-evaluation-of-immune-globulin-intravenous-10-in-the-treatment-of-primary-immunodeficiency/2024-11-14T13:19:04-05:00https://healix.net/clinical-outcomes/real-world-utilization-of-immune-globulin-subcutaneous-16-5-in-treatment-naive-primary-immunodeficient-patients/2024-11-14T13:18:17-05:00https://healix.net/clinical-outcomes/real-world-utilization-of-immune-globulin-intravenous-10-at-physician-office-infusion-centers/2024-11-14T13:15:49-05:00https://healix.net/new-therapies-programs/real-world-ustekinumab-use-in-pediatric-patients-with-crohns-disease/2024-11-14T13:13:56-05:00https://healix.net/clinical-outcomes/management-of-home-parenteral-nutrition-in-gastroenterology-office-infusion-centers/2024-11-14T13:04:03-05:00https://healix.net/new-therapies-programs/real-world-experience-with-microbiota-treatment-for-the-prevention-of-recurrent-clostridioides-difficile-infection/2024-11-12T15:49:00-05:00https://healix.net/infusion-management-services/drug-procurement-services/2026-08-12T07:50:46-04:00https://healix.net/infusion-management-services/revenue-cycle-services/2026-08-12T08:23:54-04:00https://healix.net/infusion-management-services/core-infusion-services/2026-08-12T08:20:53-04:00https://healix.net/infusion-management-services/nursing-infusion-services/2026-08-12T08:03:20-04:00https://healix.net/infusion-management-services/pharmacy-infusion-services/2026-08-12T08:39:07-04:00https://healix.net/services/infusion-management-services/2026-08-12T10:13:33-04:00https://healix.net/services/ambulatory-infusion-centers/2026-08-06T11:08:43-04:00https://healix.net/services/pharmacy-services/2026-08-12T07:07:41-04:00https://healix.net/services/wholesale-distribution/2026-08-12T07:05:40-04:00https://healix.net/services/outcomes-research/2026-08-12T08:31:38-04:00https://healix.net/services/outsourced-patient-support-and-hub-services/2026-08-06T06:46:10-04:00https://healix.net/news/national-infusion-center-association-nica-annual-conference-2025/2025-07-09T15:29:18-04:00https://healix.net/news/lets-connect-at-asembias-summit/2025-04-24T17:06:10-04:00https://healix.net/news/consortium-of-multiple-sclerosis-centers-cmsc-annual-meeting-2025/2025-04-17T16:12:59-04:00https://healix.net/news/american-academy-of-neurology-aan-2025-annual-meeting/2025-03-26T10:01:56-04:00https://healix.net/news/state-of-texas-association-of-rheumatologists-star-2025-annual-meeting/2025-02-14T15:56:04-05:00https://healix.net/news/healix-celebrates-35-years-in-sugar-land/2024-12-04T12:05:58-05:00https://healix.net/news/meet-the-healix-team-at-idweek-2024/2024-08-20T13:48:31-04:00https://healix.net/news/national-organization-of-rheumatology-management-norm-2024-annual-conference/2026-08-06T06:46:11-04:00https://healix.net/news/video-highlight-nationwide-pharmacy-services-for-patient-specific-injectable-and-infused-medications/2024-02-19T16:40:24-05:00https://healix.net/news/idsa-honors-219-distinguished-physicians-scientists/2023-10-18T17:44:13-04:00https://healix.net/news/meet-the-healix-team-at-idweek-2023/2023-10-04T11:12:13-04:00https://healix.net/news/high-adherence-and-cost-savings-with-home-opat-provided-through-infectious-disease-physician-office-infusion-centers/2023-01-27T13:27:07-05:00https://healix.net/news/norm-2022/2022-08-22T14:20:27-04:00https://healix.net/news/transition-to-igsc-improves-patient-reported-quality-of-life/2022-07-01T15:50:59-04:00https://healix.net/news/tns-summer-conference-2022/2022-06-07T17:06:35-04:00https://healix.net/news/nla-scientific-sessions-2022/2022-05-16T11:56:23-04:00https://healix.net/news/gsr-2022-annual-meeting/2022-05-11T11:41:31-04:00https://healix.net/news/ccr-east-2022/2022-04-19T16:25:26-04:00https://healix.net/clinical-outcomes/3-year-evaluation-of-antibiotic-resistance-patterns-in-gram-negative-gti/2022-03-01T16:34:52-05:00https://healix.net/news/the-impact-of-covid-19-on-outpatient-intravenous-antimicrobial-therapy-opat-in-physician-office-infusion-centers-poics/2022-02-25T10:38:31-05:00https://healix.net/news/a-3-year-evaluation-of-antibiotic-resistance-patterns-in-gram-negative-genitourinary-tract-infections-treated-in-outpatient-infusion-centers-poics/2022-02-25T10:39:53-05:00https://healix.net/news/star-2022-annual-meeting/2022-01-28T11:46:06-05:00https://healix.net/news/aaaai-2022-annual-meeting/2022-01-31T11:43:11-05:00https://healix.net/news/acaai-2021-annual-scientific-meeting/2021-11-04T12:33:05-04:00https://healix.net/events/healix-collaborative-research-at-acg-2021/2021-11-04T12:30:18-04:00https://healix.net/news/immunoglobulin-national-society-igns-national-conference/2021-11-04T12:32:13-04:00https://healix.net/news/national-organization-of-rheumatology-managers-annual-meeting/2021-09-26T15:52:45-04:00https://healix.net/news/idweek-2021-virtual-conference/2021-10-20T15:20:43-04:00https://healix.net/news/florida-society-of-neurology-annual-meeting/2021-09-09T15:38:02-04:00https://healix.net/news/covid-19-pandemic-initial-impact-on-outpatient-ivab-therapy/2021-08-19T17:25:55-04:00https://healix.net/news/covid-19-pandemic-impact-on-infusion-utilization/2021-08-19T17:26:53-04:00https://healix.net/news/happy-national-pharmacy-week-from-healix/2021-08-19T17:31:56-04:00https://healix.net/news/american-college-of-allergy-asthma-immunology-acaai-annual-meeting-2/2020-10-28T14:25:42-04:00https://healix.net/news/american-college-of-gastroenterology-acg-annual-meeting-2/2020-10-19T09:57:37-04:00https://healix.net/news/idweek2020/2020-10-15T17:28:40-04:00https://healix.net/news/immunoglobulin-national-society-igns-9th-national-conference-2020/2020-10-15T17:59:24-04:00https://healix.net/news/hospital-avoidance-provision-opat/2021-08-19T17:35:08-04:00https://healix.net/news/first-real-world-study-of-immune-globulin-subcutaneous-cutaquig-featured-aaaai-annual-meeting/2021-08-19T17:36:30-04:00https://healix.net/news/national-nurses-week/2021-08-19T17:37:04-04:00https://healix.net/news/bezlotoxumab-real-world-study-demonstrates-success-in-prevention-of-clostridioides-difficile-infection/2021-08-19T17:45:49-04:00https://healix.net/news/healthcare-heroes/2021-08-19T17:37:18-04:00https://healix.net/cost-savings/successful-early-discharge-and-avoided-hospitalization-for-methicillin-resistant-staphylococcus-aureus-mrsa-infections-treated-with-outpatient-parenteral-antimicrobial-therapy-opat-result-in-healt/2024-10-30T09:59:15-04:00https://healix.net/cost-savings/a-2-year-analysis-of-30-day-hospital-readmissions-and-cost-benefits-of-septicemia-outpatient-treatment-in-a-physician-office-infusion-center-poic/2020-06-10T16:01:22-04:00https://healix.net/cost-savings/cost-comparison-of-outpatient-antimicrobial-therapy-opat-in-a-physician-office-infusion-center-poic-vs-traditional-home-health-care-hhc/2020-06-12T12:36:54-04:00https://healix.net/cost-savings/cost-savings-utilizing-outpatient-parenteral-antimicrobial-therapy-opat-for-treatment-of-complicated-skin-and-skin-structure-infections-csssi-in-physician-operated-infusion-centers-poics-without/2020-06-12T12:42:34-04:00https://healix.net/clinical-outcomes/outpatient-treatment-of-osteomyelitis-with-telavancin/2020-06-12T12:47:56-04:00https://healix.net/clinical-outcomes/outpatient-treatment-of-infective-endocarditis-at-physician-office-infusion-centers-poics-a-2-year-analysis-of-clinical-and-economic-outcomes/2020-06-12T12:46:09-04:00https://healix.net/clinical-outcomes/real-world-comparison-of-arthralgias-with-infliximab-vs-vedolizumab-in-the-treatment-of-bio-naive-inflammatory-bowel-disease/2020-06-12T12:51:25-04:00https://healix.net/clinical-outcomes/outpatient-treatment-and-recurrence-of-prosthetic-joint-infection-pji-treated-in-infectious-disease-id-physician-office-infusion-centers-poics-a-2-year-retrospective-multicenter-analysis/2020-03-04T15:58:29-05:00https://healix.net/special-populations/real-world-experience-of-vedolizumab-in-pediatric-inflammatory-bowel-disease/2020-03-04T15:59:27-05:00https://healix.net/special-populations/safety-and-effectiveness-of-outpatient-parenteral-antimicrobial-therapy-opat-in-the-aged-population/2020-03-04T16:00:13-05:00https://healix.net/persistence/tolerability-and-persistence-with-subcutaneous-immunoglobulin-provided-through-physician-clinics-for-the-treatment-of-primary-immunodeficiencies/2020-03-04T16:01:03-05:00https://healix.net/new-therapies-programs/effective-antimicrobial-stewardship-for-outpatient-antimicrobial-therapy-opat-nationwide-experience-in-infectious-diseases-physician-infusion-centers/2020-03-04T16:02:04-05:00https://healix.net/new-therapies-programs/evaluation-of-bezlotoxumab-in-prevention-of-recurrent-c-difficile-infection-a-multicenter-single-arm-study-in-office-infusion-centers/2020-03-04T16:03:04-05:00https://healix.net/new-therapies-programs/healthcare-resource-utilization-for-high-risk-patients-treated-with-dalbavancin-in-physician-office-infusion-centers/2020-03-04T16:03:52-05:00https://healix.net/events/state-of-texas-association-of-rheumatologists-star/2020-02-20T16:53:21-05:00https://healix.net/clinical-outcomes/predictors-of-vedolizumab-treatment-persistence-in-bio-naive-ulcerative-colitis-patients/2020-03-04T12:55:22-05:00https://healix.net/events/trs/2020-02-05T15:45:32-05:00https://healix.net/clinical-outcomes/real-world-prescribing-patterns-of-certolizumab-in-the-treatment-of-crohns-disease/2020-03-04T13:33:10-05:00https://healix.net/clinical-outcomes/onset-of-response-with-infliximab-vs-vedolizumab-in-the-treatment-of-bio-naive-inflammatory-bowel-disease/2020-03-04T13:12:40-05:00https://healix.net/clinical-outcomes/second-line-biologic-therapy-after-vedolizumab/2020-03-04T13:12:00-05:00https://healix.net/special-populations/long-term-efficacy-of-vedolizumab-in-pediatric-inflammatory-bowel-disease/2020-03-04T13:11:18-05:00https://healix.net/special-populations/use-of-ustekinumab-in-pediatric-crohns-disease-a-report-of-three-cases/2020-03-04T12:58:57-05:00https://healix.net/cost-savings/response-and-healthcare-resource-utilization-in-inflammatory-bowel-disease-patients-treated-with-either-infliximab-or-vedolizumab/2020-03-04T12:57:43-05:00https://healix.net/news/30th-anniversary/2019-10-30T12:37:28-04:00https://healix.net/cost-savings/low-30-day-hospital-readmission-rates-in-medicare-patients-receiving-outpatient-parenteral-antimicrobial-therapy-opat-in-physician-office-infusion-centers/2020-03-04T13:23:42-05:00https://healix.net/clinical-outcomes/serious-bacterial-infections-successful-outpatient-management-by-infectious-disease-physicians-in-office-infusion-centers/2020-03-04T13:18:11-05:00https://healix.net/new-therapies-programs/recurrent-clostridioides-difficile-infection-cdi-worsens-anxiety-related-patient-reported-quality-of-life/2020-03-04T13:29:06-05:00https://healix.net/clinical-outcomes/real-world-use-of-ibalizumab-in-poics/2020-03-04T13:20:06-05:00https://healix.net/events/american-college-of-rheumatology-acr-annual-meeting/2019-08-26T15:13:50-04:00https://healix.net/events/american-college-of-allergy-asthma-immunology-acaai-annual-meeting/2019-08-26T14:45:51-04:00https://healix.net/events/american-college-of-gastroenterology-acg-annual-meeting/2019-08-26T14:43:17-04:00https://healix.net/events/chest-annual-meeting/2019-08-26T14:39:20-04:00https://healix.net/events/idweek/2019-08-26T14:35:15-04:00https://healix.net/events/rheumatology-association-of-minnesota-and-dakotas-ra-md/2019-08-26T14:32:25-04:00https://healix.net/events/congress-of-clinical-rheumatology-ccr-symposium/2019-08-26T14:30:17-04:00https://healix.net/events/illinois-state-neurological-society-isns-annual-meeting/2019-08-26T14:26:36-04:00https://healix.net/events/virginia-society-of-rheumatologists-32nd-annual-scientific-meeting/2019-08-26T14:22:15-04:00https://healix.net/events/12th-annual-perspectives-in-rheumatic-diseases-annual-meeting/2019-08-26T14:19:23-04:00https://healix.net/events/florida-society-of-neurology-fsn-annual-meeting/2019-08-26T14:14:18-04:00https://healix.net/events/national-organization-of-rheumatology-managers-norm-annual-meeting/2019-09-10T13:31:50-04:00https://healix.net/events/rheumatology-society-of-new-mexico-rsnm/2019-08-26T14:05:29-04:00https://healix.net/events/missouri-kansas-neurological-society-annual-meeting/2019-08-26T14:00:35-04:00https://healix.net/events/long-island-allergy-asthma-society-liaas-annual-meeting/2019-08-26T13:56:08-04:00https://healix.net/events/ohio-association-of-rheumatology-oar-annual-meeting/2019-08-07T15:22:34-04:00https://healix.net/events/gi-outlook/2019-07-30T11:54:07-04:00https://healix.net/news/healix-infusion-therapy-selected-as-limited-distribution-network-partner-for-cutaquig/2022-01-27T17:41:54-05:00https://healix.net/events/texas-infectious-diseases-society-tids-annual-meeting/2019-07-30T12:05:56-04:00https://healix.net/events/arizona-united-rheumatology-alliance-aura-annual-meeting/2019-05-30T11:49:41-04:00https://healix.net/events/georgia-society-of-rheumatology-gsr-annual-meeting/2019-05-30T11:57:15-04:00https://healix.net/events/consortium-of-multiple-sclerosis-centers-cmsc-annual-meeting/2019-05-30T11:52:58-04:00https://healix.net/events/digestive-disease-week-ddw/2019-05-30T11:54:59-04:00https://healix.net/new-therapies-programs/application-of-bayesian-modeling-with-infliximab-to-determine-optimal-patient-specific-regimen/2020-03-04T14:05:51-05:00https://healix.net/blog/temporary-placeholder-for-a-sample-blog-post/2020-04-14T15:34:40-04:00https://healix.net/events/american-academy-of-neurology-aan-annual-meeting/2019-05-30T11:47:20-04:00https://healix.net/news/healix-selects-citus-health-to-digitally-transform-communication-streams-and-care-coordination/2019-05-29T15:07:48-04:00https://healix.net/new-therapies-programs/tolerability-and-persistence-with-subcutaneous-immunoglobulin-provided-through-physician-clinics-for-the-treatment-of-primary-immunodeficiencies-2/2020-03-04T13:55:09-05:00https://healix.net/news/healix-announces-strategic-partnership-with-weinfuse/2019-05-21T16:10:36-04:00https://healix.net/clinical-outcomes/failure-of-vedolizumab-as-first-line-biologic-does-not-increase-response-rate-of-second-line-therapy/2019-07-30T12:15:29-04:00https://healix.net/clinical-outcomes/therapeutic-drug-monitoring-of-biologics-in-patients-with-inflammatory-bowel-disease-a-real-world-experience/2019-06-24T11:26:18-04:00https://healix.net/clinical-outcomes/mandated-payor-switching-with-infliximab-ifx-bioimilars/2019-06-24T11:26:58-04:00https://healix.net/clinical-outcomes/healthcare-resource-utilization-in-inflammatory-bowel-disease-patients-a-2-year-analysis/2019-06-24T11:27:28-04:00https://healix.net/new-therapies-programs/infection-incidence-and-utilization-of-antimicrobials-in-physician-office-infusion-centers-poics/2024-10-23T17:57:13-04:00https://healix.net/news/healix-announces-strategic-partnership-with-doseme-for-precision-dosing/2019-05-21T16:12:10-04:00https://healix.net/clinical-outcomes/real-world-experience-of-bezlotoxumab-for-prevention-of-recurrent-c-difficile-infection-a-single-arm-multicenter-pilot-study-in-office-infusion-centers/2020-03-04T13:42:28-05:00https://healix.net/clinical-outcomes/real-word-evaluation-of-prolonged-clinical-response-with-vedolizumab-in-crohns-disease-and-ulcerative-colitis-patients-treated-in-a-private-practice-setting/2020-03-03T15:56:58-05:00https://healix.net/news/ta-associates-announces-investment-in-healix/2019-05-28T14:00:09-04:00https://healix.net/clinical-outcomes/long-term-safety-analysis-of-vedolizumab-for-treatment-of-crohns-disease-and-ulcerative-colitis-2/2019-06-24T11:28:35-04:00https://healix.net/clinical-outcomes/can-vedolizumab-non-responders-be-treated-successfully-with-another-biologic-agent/2020-05-27T16:35:02-04:00https://healix.net/clinical-outcomes/successful-establishment-of-an-antimicrobial-stewardship-program-asp-for-outpatient-parenteral-antimicrobial-therapy-opat/2020-03-04T14:00:28-05:00https://healix.net/news/healix-relocates-to-new-state-of-the-art-pharmacy-facility-in-sugar-land-texas/2019-11-15T11:26:24-05:00https://healix.net/news/healix-is-now-a-national-provider-of-trogarzo-ibalizumab-uiyk/2019-05-21T16:20:06-04:00https://healix.net/news/outpatient-treatment-of-osteomyelitis-with-telavancin-2/2019-05-28T10:35:25-04:00https://healix.net/cost-savings/clinical-and-economic-outcomes-of-outpatient-parenteral-antimicrobial-therapy-opat-among-indigent-patients-a-retrospective-multicenter-analysis-2/2019-06-26T15:46:32-04:00https://healix.net/news/healix-is-now-a-national-provider-of-cuvitru-immune-globulin-subcutaneous-human-20/2019-05-21T16:22:47-04:00https://healix.net/clinical-outcomes/outpatient-treatment-of-infective-endocarditis-ie-at-physician-office-infusion-centers-poics-a-2-year-analysis-of-clinical-and-economic-outcomes/2019-06-04T12:34:14-04:00https://healix.net/new-therapies-programs/ceftolozane-tazobactam-outpatient-treatment-of-gram-negative-infections-at-physician-office-infusion-centers-poics/2020-03-04T14:09:02-05:00https://healix.net/cost-savings/successful-early-discharge-and-avoided-hospitalization-for-methicillin-resistant-staphylococcus-aureus-infections-treated-with-outpatient-parenteral-antimicrobial-therapy-result-in-healthcare-cost-sav/2020-03-04T13:56:45-05:00https://healix.net/news/dalbavancin-a-nationwide-outpatient-experience-in-physician-office-infusion-centers/2019-06-11T10:57:24-04:00https://healix.net/news/antimicrobial-regimen-and-safety-of-pediatric-outpatient-treatment-in-a-poic/2019-06-11T10:53:48-04:00https://healix.net/news/a-2-year-analysis-of-30-day-hospital-readmissions-and-cost-benefits-of-septicemia-opat-in-a-poic/2019-06-11T10:50:01-04:00https://healix.net/clinical-outcomes/successful-management-of-osteomyelitis-in-infectious-disease-physician-office-infusion-centers-poics/2020-03-04T14:10:50-05:00https://healix.net/special-populations/antimicrobial-regimen-and-safety-of-pediatric-outpatient-treatment-in-a-physician-office-infusion-center-poic-2/2020-03-04T14:04:19-05:00https://healix.net/clinical-outcomes/antimicrobial-regimen-and-safety-of-pediatric-outpatient-treatment-in-a-physician-office-infusion-center-poic/2019-06-04T12:23:48-04:00https://healix.net/new-therapies-programs/dalbavancin-a-nationwide-outpatient-experience-in-physician-office-infusion-centers-poics/2019-06-05T08:16:14-04:00https://healix.net/news/low-hospital-admission-rates-following-poic-based-outpatient-treatment-with-intravenous-antibiotics/2019-06-11T10:58:43-04:00https://healix.net/news/comparison-of-outpatient-antimicrobial-therapy-opat-in-a-poic-vs-traditional-home-health-care/2019-06-11T11:06:01-04:00https://healix.net/cost-savings/low-hospital-admission-rates-following-physician-office-infusion-center-poic-based-outpatient-treatment-with-intravenous-antibiotics/2019-06-04T09:29:17-04:00https://healix.net/news/clinical-success-in-outpatient-treatment-of-complicated-urinary-tract-infections-with-ertapenem/2019-06-11T11:06:38-04:00https://healix.net/news/clinical-economic-outcomes-of-outpatient-parenteral-antimicrobial-therapy-among-indigent-patients/2019-06-11T10:54:51-04:00https://healix.net/news/outpatient-parenteral-antimicrobial-therapy-for-treatment-of-complicated-intra-abdominal-infections/2019-06-12T16:42:37-04:00https://healix.net/news/vancomycin-van-experience-in-physician-office-infusion-centers-poics/2019-06-11T11:03:04-04:00https://healix.net/clinical-outcomes/outpatient-parenteral-antimicrobial-therapy-opat-for-treatment-of-complicated-intra-abdominal-infections/2019-06-04T12:14:39-04:00https://healix.net/clinical-outcomes/vancomycin-experience-in-physician-office-infusion-centers/2019-06-04T12:14:58-04:00https://healix.net/clinical-outcomes/clinical-success-in-outpatient-treatment-of-complicated-urinary-tract-infections-uti-with-ertapenem/2019-06-04T11:42:35-04:00https://healix.net/news/successful-treatment-of-polymicrobial-calcaneal-osteomyelitis/2019-06-11T11:00:58-04:00https://healix.net/news/c-difficile-associated-diarrhea-incidence-outcomes-in-physician-office-infusion-centers/2019-06-11T10:54:23-04:00https://healix.net/news/cost-outcomes-comparison-of-patients-whose-treatment-began-in-infusion-center-vs-after-discharge/2019-06-11T10:56:56-04:00https://healix.net/news/outcomes-comparison-of-iv-antimicrobials-in-an-office-infusion-center-vs-home-care-services/2019-06-11T11:00:11-04:00https://healix.net/news/utilization-of-iv-antimicrobials-over-a-one-year-period-in-physician-office-infusion-centers/2019-06-11T11:02:23-04:00https://healix.net/news/successful-cost-saving-outpatient-parenteral-antimicrobial-therapy-following-hospital-discharge/2019-06-27T09:39:14-04:00https://healix.net/clinical-outcomes/clostridium-difficile-associated-diarrhea-incidence-and-outcomes-for-patients-treated-with-intravenous-antibiotics-in-infectious-disease-physician-office-infusion-centers-poics/2019-06-04T11:29:40-04:00https://healix.net/clinical-outcomes/comparison-of-outcomes-and-costs-in-patients-with-urinary-tract-infections-uti-or-pneumonia-pna-with-treatment-initiated-in-a-physician-office-infusion-center-poic-versus-those-treated-after-hos/2019-06-04T11:26:19-04:00https://healix.net/cost-savings/utilization-of-intravenous-antimicrobials-over-a-one-year-period-in-physician-office-infusion-centers-poics/2019-06-04T09:20:26-04:00https://healix.net/cost-savings/successful-cost-saving-outpatient-parenteral-antimicrobial-therapy-opat-following-hospital-discharge-early-pilot-study-of-an-indigent-healthcare-program-between-a-physician-office-infusion-center/2019-06-04T09:20:17-04:00https://healix.net/cost-savings/outcomes-comparison-of-intravenous-antimicrobials-provided-in-a-physician-office-infusion-center-poic-versus-traditional-home-care-hc-services/2019-06-04T09:20:11-04:00https://healix.net/clinical-outcomes/incidence-of-central-venous-catheter-cvc-infections-in-patients-treated-with-intravenous-antibiotics-ivab-in-the-physician-office-infusion-center-poic/2019-06-04T11:17:56-04:00https://healix.net/news/low-rates-of-c-difficile-associated-diarrhea-in-patients-receiving-ivab-in-the-outpatient-setting/2019-06-11T10:59:13-04:00https://healix.net/news/low-readmission-and-recurrence-rates-of-bacteremia-endocarditis-osteomyelitis-in-infusion-centers/2019-06-11T10:59:35-04:00https://healix.net/news/treatment-with-iv-antibiotics-in-an-outpatient-poic-shows-successful-outcomes-and-cost-savings/2019-06-11T11:02:01-04:00https://healix.net/news/telavancin-treatment-in-the-outpatient-setting-is-effective/2019-05-28T10:38:10-04:00https://healix.net/clinical-outcomes/outcomes-and-readmissions-of-bacteremia-endocarditis-and-osteomyelitis-among-patients-treated-with-outpatient-parenteral-antimicrobial-therapy-opat-in-infectious-disease-physician-office-infusion-c/2019-06-04T11:15:39-04:00https://healix.net/clinical-outcomes/clostridium-difficile-associated-diarrhea-incidence-and-outcomes-for-patients-treated-with-intravenous-antibiotics-in-infectious-disease-physician-office-infusion-centers/2019-06-04T11:11:48-04:00https://healix.net/cost-savings/successful-cost-saving-opat-therapy-initiated-in-a-physician-office-infusion-center-poic-for-treatment-of-osteomyelitis-and-complicated-skin-and-skin-structure-infections-a-3-year-analysis/2019-06-04T09:20:05-04:00https://healix.net/new-therapies-programs/outpatient-parenteral-antibiotic-therapy-opat-with-telavancin-a-multi-center-experience/2019-06-05T08:11:29-04:00https://healix.net/news/healix-launches-new-app-to-boost-client-efficiency/2019-05-28T14:06:47-04:00https://healix.net/clinical-outcomes/clinical-success-demonstrated-in-treatment-of-complicated-genitourinary-gram-negative-infections-in-a-physician-office-infusion-center-poic/2019-06-04T11:09:22-04:00https://healix.net/clinical-outcomes/successful-treatment-of-complicated-gram-negative-sinopulmonary-infections-treated-in-infectious-disease-id-physician-office-infusion-centers-poics/2019-06-04T10:58:40-04:00https://healix.net/cost-savings/infection-control-enhancements-through-successful-implementation-of-united-states-pharmacopeia-chapter-standards-usp-797-in-a-physician-infusion-center-pharmacy/2019-06-04T09:19:57-04:00https://healix.net/cost-savings/safety-efficacy-and-cost-benefit-of-initiating-treatment-of-osteomyelitis-and-complicated-skin-and-skin-structure-infections-in-a-physician-office-based-infusion-center-a-two-year-review/2019-06-04T09:19:51-04:00https://healix.net/clinical-outcomes/treatment-of-osteomyelitis-in-infectious-disease-physician-operated-infusion-centers-poics/2019-06-04T10:49:30-04:00https://healix.net/cost-savings/safety-and-efficacy-of-direct-physician-office-based-infusion-center-poic-admissions-for-antibiotic-treatment-of-osteomyelitis-osteo-and-complicated-skin-and-skin-structure-infections-csssi/2019-06-04T09:19:39-04:00https://healix.net/clinical-outcomes/parenteral-antimicrobial-therapy-initiated-in-the-infectious-disease-id-physician-office-what-and-why/2019-06-04T10:37:29-04:00https://healix.net/clinical-outcomes/comparison-of-outpatient-antibiotic-therapy-opat-use-of-daptomycin-linezolid-quinupristin-dalfopristin-tigecycline-and-vancomycin-in-physician-operated-infusion-centers-poics/2020-04-14T16:47:28-04:00